Related Experiment Video
Updated: Jul 16, 2026

Protocol for Relative Hydrodynamic Assessment of Tri-leaflet Polymer Valves
Published on: October 17, 2013
Bioprosthetic valve degeneration due to cholesterol deposition in a patient with normal lipid profile
Leslie Price1, Allan Sniderman, Attila Omerglu
1McGill University Health Centre, Montreal, Quebec.
Insights
High cholesterol contributes to bioprosthetic valve degeneration. However, this case shows it can occur even with low cholesterol levels, suggesting valve characteristics are key.
Area of Science:
- Cardiovascular Medicine
- Biomaterials Science
Background:
- Hypercholesterolemia is a known risk factor for bioprosthetic valvular degeneration.
- Statin therapy is hypothesized to mitigate this risk.
Observation:
- A 77-year-old male patient exhibited significant low-density lipoprotein cholesterol (LDL-C) crystal deposition.
- This occurred 21.5 years post-aortic bioprosthetic replacement, alongside a foreign body giant cell reaction.
- The patient presented with previously low LDL-C and apolipoprotein B levels.
Findings:
- Confirms cholesterol deposition as a contributor to bioprosthetic valve degeneration.
- Demonstrates that severe degeneration can manifest even in patients with low LDL-C.
- Highlights the potential primacy of valve material characteristics over patient LDL-C levels.
Implications:
- Challenges the sole reliance on LDL-C levels for assessing bioprosthetic valve degeneration risk.
- Suggests further investigation into biomaterial properties influencing long-term valve performance.
- Informs clinical management strategies for patients with bioprosthetic heart valves.
Abstract:
Hypercholesterolemia has been identified as a risk factor for bioprosthetic valvular degeneration, and it has been suggested that statin therapy reduces this risk. The case of a 77-year-old man with low levels of low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B who developed marked LDL-C crystal deposition and a severe foreign body giant cell reaction 21.5 years after aortic bioprosthetic replacement is reported. This observation confirms that cholesterol deposition contributes to bioprosthetic valve degeneration, but that this can occur even in patients with low levels of LDL-C. It suggests that the characteristics of the valve are more critical than the patient's level of LDL-C.
Related Concept Videos
Mitral Valve Prolapse I: Introduction
Atherosclerosis I: Introduction
Peripheral Artery Disease I: Introduction
Coronary Artery Disease II: Pathophysiology
Degenerative Disc Disease I: Introduction
Inflammation

